Back to News
Market Impact: 0.35
Kyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock Down
Source: Nasdaq
Healthcare & Biotech
Kyverna Therapeutics reported one-year results from its registrational Phase 2 KYSA-8 trial, showing sustained clinical benefits of miv-cel in patients with stiff person syndrome. The report provides no numerical efficacy or safety data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
KYTX0.75
More News
- Kyverna reports one-year data for SPS therapy miv-cel
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Arcus Biosciences prices $250 million stock offering at $17.50
- AstraZeneca says U.S. FDA approves rare kidney disease drug
- UnitedHealth's Earnings Jumped 60%. Is the Comeback Stock a Buy, Sell, or Hold?
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can ChatGPT or Claude Replace a Research Platform?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance